Early treatment study
et al., Int. J. of Antimicrobial Agents, 17 March 2020, doi:10.1016/j.ijantimicag.2020.105949 (Peer Reviewed)
Hydroxych loroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial
HC Q significantly associated with viral load reduction / elimination, enhanced with AZ. This early and small trial has significant limitations, larger and more recent trials by the same group confirm the results.
Please send us corrections, updates, or comments.